Data / Research funding / Pulmonary Hypertension
Pulmonary Hypertension: 366 NIH awards ($467.8M) to 106 organizations
366 NIH awards ($467.8M) in the NIH spending category Pulmonary Hypertension, to 106 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
366 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Complement Mediated Remodeling in Pulmonary Vascular Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $11,355,302 | August 1, 2020 | June 30, 2026 | STENMARK, KURT R. | reporter.nih.gov |
| Sickle Cell Disease and Cardiovascular Risk- Red Cell Exchange SCD-CARRE | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $9,739,425 | September 1, 2022 | April 30, 2027 | GLADWIN, MARK T | reporter.nih.gov |
| Safety of Sildenafil in Premature Infants with Severe Bronchopulmonary Dysplasia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $6,819,944 | September 15, 2019 | August 31, 2025 | HORNIK, CHRISTOPH | reporter.nih.gov |
| Physical Activity in Pulmonary Arterial Hypertension (ACTiPH) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $5,556,139 | August 20, 2021 | May 31, 2027 | KAWUT, STEVEN M | reporter.nih.gov |
| Novel vascular smooth muscle cell progenitors in development and disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,999,830 | July 1, 2020 | June 30, 2027 | GREIF, DANIEL | reporter.nih.gov |
| Noninvasive measurement of oxygenation using quantitative susceptibility mapping | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,679,068 | January 1, 2021 | December 31, 2026 | SPINCEMAILLE, PASCAL | reporter.nih.gov |
| 2/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,771,268 | May 15, 2019 | April 30, 2027 | BROOKS, MARIA MORI | reporter.nih.gov |
| Case-Control Study of Methamphetamine in Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,677,031 | August 20, 2021 | May 31, 2027 | KAWUT, STEVEN M | reporter.nih.gov |
| 1/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $3,567,710 | May 15, 2019 | August 31, 2022 | GLADWIN, MARK T | reporter.nih.gov |
| Tricuspid Valve Maladaptation: Its Stimuli, its Effect on Valve Function, and its Response to Therapy | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,537,887 | June 20, 2022 | May 31, 2027 | RAUSCH, MANUEL KARL | reporter.nih.gov |
| Endothelial-pericyte interactions in the pathogenesis of pulmonary arterial hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,307,657 | December 7, 2017 | June 30, 2027 | DE JESUS PEREZ, VINICIO A | reporter.nih.gov |
| Genomics of Pulmonary Vascular Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,302,250 | April 1, 2018 | March 31, 2025 | ALDRED, MICHEALA A | reporter.nih.gov |
| 2/2 Kids MoD PAH Trial: Mono- vs. Duo-Therapy for Pediatric Pulmonary Arterial Hypertension-DCC | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,234,679 | September 15, 2021 | November 30, 2026 | CHAKRABORTY, HRISHIKESH | reporter.nih.gov |
| The state of energy in the right ventricle of patients with pulmonary arterial hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,198,508 | January 15, 2022 | December 31, 2026 | KHERADVAR, ARASH | reporter.nih.gov |
| 1/2 Kids MoD PAH Trial: Mono- vs. Duo-Therapy In Pediatric Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $3,169,398 | September 15, 2021 | May 31, 2026 | ROMER, LEWIS H | reporter.nih.gov |
| Risk stratification in pulmonary arterial hypertension: Intersection of OMICs and longitudinal phenotypes through the PAH Biobank | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,154,051 | September 1, 2022 | June 30, 2026 | NICHOLS, WILLIAM C | reporter.nih.gov |
| Multiscale mechanobiology of right ventricular failure | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,148,570 | July 1, 2020 | June 30, 2025 | CHESLER, NAOMI C | reporter.nih.gov |
| Molecular pathogenesis of pulmonary arterial hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,134,947 | May 1, 2021 | January 31, 2026 | HATA, AKIKO | reporter.nih.gov |
| Mechanisms of newborn pulmonary hypertension caused by chronic intrauterine hypoxia | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,098,160 | January 1, 2022 | November 30, 2026 | BLOOD, ARLIN B | reporter.nih.gov |
| 2-HOBA for Treatment of Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $3,088,886 | September 1, 2021 | August 31, 2026 | RATHMACHER, JOHN A | reporter.nih.gov |
| An endothelial-fibroblast axis connecting senescence to amino acid metabolism for control of vascular stiffness in PAH | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,085,449 | September 1, 2014 | April 30, 2027 | CHAN, STEPHEN Y | reporter.nih.gov |
| Clinical and Mechanistic Understanding of Right Ventricular Steatosis in Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,053,152 | August 25, 2022 | July 31, 2027 | BRITTAIN, EVAN L | reporter.nih.gov |
| The emerging role of apelin, RAAS, and ACE2 crosstalk in pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,037,281 | August 1, 2022 | July 31, 2027 | FRUMP, ANDREA LEE | reporter.nih.gov |
| Classification and Prognostication in Pulmonary Thromboembolism Using Computed Tomography Image Analytics | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,024,998 | September 1, 2022 | June 30, 2027 | RAHAGHI, FARBOD NICHOLAS | reporter.nih.gov |
| MK2 and pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,996,274 | September 20, 2021 | May 31, 2026 | SHIMODA, LARISSA A. | reporter.nih.gov |
| Development of a Novel Hyaluronan Inhibitor for the Treatment of Group 3 Pulmonary Hypertension (PH) | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $2,993,376 | May 15, 2024 | April 30, 2027 | PALADINI, RUDY | reporter.nih.gov |
| Genomic and Circulating Predictors of PAH response | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,985,514 | May 15, 2019 | April 30, 2028 | HEMNES, ANNA R | reporter.nih.gov |
| Chemical-based Nitric Oxide Gas-generating Drug Device for the Treatment of Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $2,946,822 | August 18, 2020 | April 30, 2026 | LESSING, GARY | reporter.nih.gov |
| Xenon MRI in Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,935,947 | June 1, 2021 | May 31, 2026 | RAJAGOPAL, SUDARSHAN K | reporter.nih.gov |
| Activation, Phenotype and Function of CD4 T Cells in Schistosoma-Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,921,561 | December 15, 2016 | August 31, 2027 | GRAHAM, BRIAN BARKLEY | reporter.nih.gov |
| Role of Skeletal Muscle in Pulmonary Vascular Remodeling | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,909,455 | August 15, 2018 | June 30, 2028 | LAI, YEN CHUN CHARLY | reporter.nih.gov |
| High Shear Stress Alters Gene Regulation in Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,889,408 | January 28, 2021 | December 31, 2025 | RABINOVITCH, MARLENE | reporter.nih.gov |
| Pathophysiologic Mechanism for Arrhythmias and Impaired Aerobic Capacity in Tetralogy of Fallot | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,871,936 | August 1, 2021 | July 31, 2027 | EGBE, ALEXANDER | reporter.nih.gov |
| The Wnt7a/ROR2 axis in the pathogenesis of pulmonary arterial hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,850,959 | February 1, 2017 | March 31, 2027 | DE JESUS PEREZ, VINICIO A | reporter.nih.gov |
| Aquaporin 1 and pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,844,256 | December 1, 2014 | June 30, 2027 | SHIMODA, LARISSA A. | reporter.nih.gov |
| Network Medicine and Systems Pharmacology to Advance Precision Medicine in Combined Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,837,772 | May 20, 2022 | April 30, 2027 | BRITTAIN, EVAN L | reporter.nih.gov |
| Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $2,817,681 | July 5, 2021 | March 31, 2025 | JEONG, SUN YONG | reporter.nih.gov |
| Galectin-3: A mediator of vascular remodeling in pulmonary arterial hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,788,785 | February 1, 2016 | January 31, 2027 | FULTON, DAVID J | reporter.nih.gov |
| Drug abuse and HIV-associated pulmonary vascular injury | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,784,947 | February 1, 2021 | December 31, 2025 | DHILLON, NAVNEET KAUR | reporter.nih.gov |
| PBK: A novel mediator of VSMC proliferation and vascular remodeling in PAH | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,727,494 | August 20, 2021 | May 31, 2026 | FULTON, DAVID J | reporter.nih.gov |
| The paradoxical response to iron in pulmonary hypertension of sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,709,179 | February 1, 2022 | January 31, 2027 | IRWIN, DAVID CHARLES | reporter.nih.gov |
| NAD-dependent Signaling and Pulmonary Vascular Remodeling in PAH | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,707,246 | March 1, 2022 | February 28, 2027 | MACHADO, ROBERTO F. | reporter.nih.gov |
| GP130 Antagonism in Porcine RV Pressure Overload | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,661,729 | May 1, 2022 | April 30, 2026 | PRINS, KURT W | reporter.nih.gov |
| Defining the cellular and molecular mechanisms driving neointimal lesion growth in pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,659,679 | March 20, 2022 | February 28, 2027 | KUMAR, MAYA ELISE | reporter.nih.gov |
| Novel roles of RNA modifications in the pathogenesis of pulmonary vascular remodeling and PAH | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,647,005 | September 1, 2022 | June 30, 2026 | ZHAO, YOU-YANG | reporter.nih.gov |
| Radiomics approach to engineering an artificial intelligence based echocardiography platform to predict cardiovascular surgery and heart failure outcomes. | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,534,991 | January 1, 2022 | December 31, 2026 | HIESINGER, WILLIAM | reporter.nih.gov |
| Automated Long-Term Oxygen Therapy Control System | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $2,534,316 | September 1, 2021 | August 31, 2025 | RYDBERG, NICK | reporter.nih.gov |
| Novel mechanisms of obliterative pulmonary vascular remodeling and severe pulmonary arterial hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,512,001 | July 1, 2016 | May 31, 2026 | ZHAO, YOU-YANG | reporter.nih.gov |
| Mechanobiology of Cardiopulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,483,485 | January 11, 2017 | December 31, 2023 | MERRYMAN, WILLIAM D | reporter.nih.gov |
| Frataxin deficiency as a cause of endothelial senescence in multiple subtypes of pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,458,467 | September 1, 2015 | May 31, 2025 | CHAN, STEPHEN Y | reporter.nih.gov |
| Regulatory T Cells and Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,455,344 | September 1, 2021 | July 31, 2025 | NICOLLS, MARK ROBERT | reporter.nih.gov |
| Role of intestinal inflammation in oxidized lipid induced pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,432,274 | February 10, 2022 | January 31, 2027 | EGHBALI, MANSOUREH | reporter.nih.gov |
| Cardiac Growth and Function Trajectories after Preterm Birth | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,418,062 | May 1, 2023 | April 30, 2028 | GOSS, KARA N | reporter.nih.gov |
| SOD3 regulation of redox sensitive signaling in pulmonary vascular diseases | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,405,731 | June 1, 2018 | May 31, 2025 | NOZIK, EVA S. | reporter.nih.gov |
| Optimal Oxygenation in Neonatal Lung Injury | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $2,377,306 | August 1, 2023 | April 30, 2028 | LAKSHMINRUSIMHA, SATYANARAYANA | reporter.nih.gov |
| Elucidating the structural insights into the BMP receptor mutations in PAH | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,371,161 | June 1, 2023 | March 31, 2027 | HATA, AKIKO | reporter.nih.gov |
| Ion Channels and Membrane Receptors in Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,367,907 | January 15, 2017 | December 31, 2023 | YUAN, JASON X J | reporter.nih.gov |
| Pulmonary Hypertension in Left Heart Disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,367,793 | June 1, 2023 | May 31, 2028 | REDFIELD, MARGARET M | reporter.nih.gov |
| Trajectories of Regional Cardiopulmonary Structure and Function in A Longitudinal Cohort of Extremely Preterm Infants | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,365,315 | May 2, 2023 | February 29, 2028 | HYSINGER, ERIK BRADFORD | reporter.nih.gov |
| Development of a novel disease modifying oral therapy for pulmonary arterial hypertension. | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $2,354,098 | August 23, 2019 | August 31, 2027 | SINGH, JAIPAL | reporter.nih.gov |
| Etiology and pathogenesis of lethal lung developmental disorders in neonates | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,325,410 | August 15, 2023 | May 31, 2027 | STANKIEWICZ, PAWEL | reporter.nih.gov |
| Inhaled Fasudil and DETA NONOate CAR-Targeted Liposomes for PAH | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $2,298,168 | September 1, 2021 | August 31, 2024 | AHSAN, FAKHRUL | reporter.nih.gov |
| Nitric Oxide in Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,291,952 | April 1, 1999 | December 31, 2025 | ERZURUM, SERPIL C. | reporter.nih.gov |
| Gestational Hypoxia and Programming of Maternal, Fetal and Newborn Vascular Function | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,289,567 | July 1, 2020 | June 30, 2025 | ZHANG, LUBO | reporter.nih.gov |
| The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,271,883 | September 1, 2022 | August 31, 2027 | BRITTAIN, EVAN L | reporter.nih.gov |
| Early Detection of Changes in Pulmonary Gas Exchange by Hyperpolarized Xe MRI | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,268,603 | February 1, 2011 | August 31, 2027 | DRIEHUYS, BASTIAAN | reporter.nih.gov |
| Deep learning for algorithmic detection of pulmonary hypertension using a combined digital stethoscope and single-lead electrocardiogram | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $2,257,000 | September 25, 2022 | August 31, 2025 | VENKATRAMAN, SUBRAMANIAM | reporter.nih.gov |
| Transcriptional and epigenetic mechanisms of alveologenesis and re-alveologenesis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $2,244,702 | March 15, 2024 | February 28, 2031 | CHEN, JICHAO | reporter.nih.gov |
| Mechanisms of right ventricle adaptation to pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,213,677 | September 1, 2019 | June 30, 2028 | LAHM, TIM | reporter.nih.gov |
| A non-invasive, automated platform for hemodynamic assessment of patients at risk of heart failure or pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,213,507 | May 5, 2023 | March 31, 2027 | MAHAJAN, AMAN | reporter.nih.gov |
| Pericytes differentiate into smooth muscle cells through HIF2a/SDF1 activation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,212,500 | January 1, 2021 | December 31, 2026 | YUAN, KE | reporter.nih.gov |
| Cardiovascular potassium channels: From molecular basis to disease therapeutics | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $2,160,901 | January 1, 2024 | December 31, 2030 | NICHOLS, COLIN G | reporter.nih.gov |
| Acetate and Endothelial Pathobiology | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,156,080 | May 15, 2023 | April 30, 2027 | ARANY, ZOLTAN P | reporter.nih.gov |
| Flow-Activated Calcium Signaling Microdomains in Small Pulmonary Arteries | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,152,942 | April 15, 2019 | March 31, 2029 | SONKUSARE, SWAPNIL K. | reporter.nih.gov |
| Platelet Metabolic Stress Induces Thrombo-Inflammation to Drive Endothelial Dysfunction in PH | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,149,840 | August 1, 2023 | July 31, 2027 | SHIVA, SRUTI | reporter.nih.gov |
| Genetic and hypoxic control of a lncRNA axis orchestrates endothelial reprogramming in pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,111,051 | September 1, 2023 | May 31, 2027 | CHAN, STEPHEN Y | reporter.nih.gov |
| Resistin regulates NLRP3 inflammasome in pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,103,150 | August 10, 2023 | July 31, 2027 | JOHNS, ROGER A | reporter.nih.gov |
| Uncertainty aware virtual treatment planning for peripheral pulmonary artery stenosis | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,093,561 | July 1, 2023 | June 30, 2028 | MARSDEN, ALISON L | reporter.nih.gov |
| Branched-chain Keto-acids and Aerobic Glycolysis in Vascular Smooth Muscle Cells | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,074,082 | May 15, 2023 | April 30, 2027 | LOSCALZO, JOSEPH | reporter.nih.gov |
| Assessing the Utility of Submaximal Cardiopulmonary Exercise Testing in Diagnosis and Treatment Management of Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $2,068,186 | September 1, 2022 | August 31, 2024 | MACCARTER, DEAN JUDSON | reporter.nih.gov |
| Role of Sphingolipid pathways in the pathobiology of PAH | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,063,877 | January 5, 2016 | June 30, 2025 | MACHADO, ROBERTO F. | reporter.nih.gov |
| Role of IGF axis in pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,052,246 | June 15, 2020 | May 31, 2025 | EVERETT, ALLEN D | reporter.nih.gov |
| Mechanobiological mechanisms of pulmonary hypertension secondary to left heart failure | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,049,302 | June 1, 2020 | April 30, 2025 | CHESLER, NAOMI C | reporter.nih.gov |
| Metabolic regulation of Ca2+ entry and endothelial-mesenchymal transition in pulmonary arterial hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,032,313 | September 20, 2021 | June 30, 2026 | SURESH, KARTHIK | reporter.nih.gov |
| A novel approach for prevention of Bronchopulmonary dysplasia in at-risk pre-term infants | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2023 | $2,015,197 | June 1, 2023 | April 30, 2024 | ACHARYA, SUCHISMITA | reporter.nih.gov |
| 1/2 A Phase 2 Study of Elafin (Tiprelestat) for the Treatment of Pulmonary Arterial Hypertension (PAH) | NIH | National Heart, Lung, and Blood Institute | 2025 | $1,998,124 | August 15, 2025 | July 31, 2026 | ZAMANIAN, ROHAM | reporter.nih.gov |
| Transcriptional Regulation of Endothelial Cells after Neonatal Lung Injury | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,984,340 | April 1, 2018 | June 30, 2027 | KALINICHENKO, VLADIMIR | reporter.nih.gov |
| Early Detection of Right Ventricular Dysfunction and Emerging Pulmonary Hypertension in Systemic Sclerosis | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,982,096 | February 1, 2023 | January 31, 2028 | MUKHERJEE, MONICA | reporter.nih.gov |
| Mitochondrial dysfunction in pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,965,521 | August 25, 2022 | June 30, 2027 | RAFIKOVA, OLGA | reporter.nih.gov |
| Clinical Decision Support for Assessing Pulmonary Embolism using Machine Learning | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $1,954,502 | February 17, 2022 | January 31, 2026 | KRAMER, KEVIN M. | reporter.nih.gov |
| Endothelium-driven signaling network in the development of pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,954,194 | September 1, 2020 | June 30, 2025 | CAI, HUA LINDA | reporter.nih.gov |
| Metabolic reprogramming of smooth muscle cells in pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,912,350 | April 1, 1998 | November 30, 2026 | BLACK, STEPHEN M | reporter.nih.gov |
| GATA-6 in pulmonary arterial hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,911,697 | March 5, 2020 | January 31, 2025 | TROJANOWSKA, MARIA | reporter.nih.gov |
| Hemolysis and Free Heme Signaling in Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,901,596 | May 1, 2020 | May 31, 2028 | RAFIKOV, RUSLAN | reporter.nih.gov |
| Novel Device to Optimize Aerosol Drug Delivery for Pulmonary Hypertension Treatment | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $1,888,338 | August 1, 2020 | August 31, 2025 | PORTERFIELD, JOHN E | reporter.nih.gov |
| Multiscale Modeling of Right Ventricular Fibrotic Remodeling in Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $1,884,844 | February 1, 2021 | January 31, 2026 | VALDEZ-JASSO, DANIELA | reporter.nih.gov |
| Role of Chromosome Y gene, Uty, in protecting against Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,882,914 | July 20, 2021 | June 30, 2025 | EGHBALI, MANSOUREH | reporter.nih.gov |
| Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $1,877,612 | September 1, 2022 | August 31, 2025 | GARCIA, JOE G. N. | reporter.nih.gov |
| Multi-scale Investigation of Sex Differences in Right Ventricular Function via Estrogen-Microtubule Interactions | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $1,813,843 | May 1, 2022 | April 30, 2027 | PRINS, KURT W | reporter.nih.gov |
| Regulation and Function of RAB7 in the pulmonary endothelium | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $1,813,425 | January 1, 2019 | June 30, 2029 | FARKAS, LASZLO | reporter.nih.gov |
| Portable electrical nitric oxide generator for treatment of pulmonary hypertension accompanying interstitial lung disease | NIH | National Center for Advancing Translational Sciences | 2021 to 2022 | $1,791,017 | August 15, 2016 | August 31, 2024 | HALL, GREG | reporter.nih.gov |
| Development of novel therapeutic approaches for treatment of Alveolar Capillary Dysplasia | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,783,643 | May 1, 2021 | May 31, 2029 | KALINICHENKO, VLADIMIR | reporter.nih.gov |
| Paracrine Action of BMP3 in Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,765,523 | August 15, 2022 | July 31, 2027 | SASSI, YASSINE | reporter.nih.gov |
| Signal transduction mechanisms that mediate normal and pathologic angiogenesis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,752,565 | April 4, 2014 | November 30, 2025 | PANG, JINJIANG | reporter.nih.gov |
| Oxidant Signaling in Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,746,731 | July 10, 2023 | June 30, 2027 | RESTA, THOMAS C | reporter.nih.gov |
| Supplemental Oxygen for Pulmonary Embolism (SO-PE) - A Mechanistic Clinical Trial | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,741,404 | September 1, 2023 | July 31, 2027 | KABRHEL, CHRISTOPHER | reporter.nih.gov |
| Photochemical Generation of Gas Phase Nitric Oxide from Immobilized S-Nitrosothiols for Biomedical Applications | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $1,730,175 | September 1, 2019 | July 31, 2025 | WOLF, ALEXANDER KEITH | reporter.nih.gov |
| A ROLE FOR EYA3 IN VASCULAR REMODELING AND PULMONARY ARTERIAL HYPERTENSION | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,713,045 | June 1, 2020 | April 30, 2025 | HEGDE, RASHMI S. | reporter.nih.gov |
| The Chromatin Remodeling Factor ARID1a and the Epigenetic Landscape In Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,678,069 | March 5, 2024 | February 28, 2028 | HADRI, LAHOUARIA | reporter.nih.gov |
| Role of Epigenetic Regulator SIN3a in Pulmonary Endothelial Cells | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,653,165 | September 15, 2024 | June 30, 2028 | HADRI, LAHOUARIA | reporter.nih.gov |
| Understanding and targeting molecular as well as structural events governing right ventricular adaptation, failure and recovery in pulmonary hypertension using repurposed drugs | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,650,653 | July 25, 2021 | May 31, 2025 | SPIEKERKOETTER, EDDA FRAUKE | reporter.nih.gov |
| SOX17/RUNX1 Axis Regulates Endothelial Cell Fate in the Pathogenesis of Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,640,000 | August 25, 2022 | June 30, 2027 | LIANG, OLIN D. | reporter.nih.gov |
| Contributions of pulmonary arterial and venous remodeling to HFpEF in the elderly | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $1,610,449 | May 15, 2022 | August 31, 2024 | SAN JOSE ESTEPAR, RAUL | reporter.nih.gov |
| Pericyte contribution to capillary remodeling in pulmonary arterial hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,604,206 | January 1, 2024 | December 31, 2027 | YUAN, KE | reporter.nih.gov |
| Cleavage of intersectin-1s by Granzyme B and Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,570,000 | September 1, 2015 | May 31, 2026 | PREDESCU, SANDA A | reporter.nih.gov |
| Mechanisms of Right Ventricular Dysfunction in Scleroderma-associated PAH | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,554,859 | August 15, 2012 | April 30, 2025 | HASSOUN, PAUL M. | reporter.nih.gov |
| Clinical, Genetic, and Proteomic Risk Factors for Pulmonary Hypertension in Heart Failure | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,547,335 | April 15, 2019 | March 31, 2025 | BRITTAIN, EVAN L | reporter.nih.gov |
| Vascular injury and repair predict divergent late onset cardiovascular morbidities after chlorine and sulfur mustard exposure | NIH | National Institute of Environmental Health Sciences | 2023 to 2025 | $1,542,275 | September 1, 2023 | August 31, 2026 | VERESS, LIVIA AGNES | reporter.nih.gov |
| Role of ADAM17 in MDSC-Mediated Development of Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,525,000 | April 5, 2020 | March 31, 2026 | BRYANT, ANDREW JUSTIN | reporter.nih.gov |
| The pathophysiology of vascular remodeling in pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,524,759 | September 6, 2024 | June 30, 2028 | PI, XINCHUN | reporter.nih.gov |
| Novel mechanisms of HIV-associated pulmonary vascular disease | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,521,520 | August 20, 2024 | May 31, 2028 | BELIN DE CHANTEMELE, ERIC J | reporter.nih.gov |
| Investigating the molecular mechanisms of right ventricular failure in pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,521,272 | September 1, 2022 | June 30, 2027 | UMAR, SOBAN | reporter.nih.gov |
| The Road to Destination Therapy: Developing a Durable Ambulatory Mechanical Cardiopulmonary Support for Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,517,495 | February 1, 2024 | January 31, 2028 | BACCHETTA, MATTHEW DOMINIC | reporter.nih.gov |
| Estrogen signaling and energy metabolism in pulmonary arterial hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,509,254 | January 1, 2018 | December 31, 2024 | AUSTIN, ERIC DOUGLAS | reporter.nih.gov |
| REVAMP-PH: REpurposing Valsartan May Protect against Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,504,525 | June 1, 2023 | June 30, 2028 | LEARY, PETER J | reporter.nih.gov |
| Pulmonary Hypertension in Genetically Modified Mice | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,502,942 | April 1, 2004 | January 31, 2024 | RABINOVITCH, MARLENE | reporter.nih.gov |
| Multidisciplinary Research Training in Pediatric Pulmonary Vascular Disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,488,759 | August 1, 2022 | July 31, 2027 | FINEMAN, JEFFREY R | reporter.nih.gov |
| Effects of DHEA in Pulmonary Hypertension (DiPH) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,479,570 | May 15, 2018 | April 30, 2025 | VENTETUOLO, COREY E | reporter.nih.gov |
| Injectable Biomaterial for Treating Hypoplastic Left Heart Syndrome | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,478,164 | January 1, 2019 | December 31, 2023 | DAVIS, MICHAEL E | reporter.nih.gov |
| HIPPO Signaling in Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,477,357 | September 1, 2020 | April 30, 2025 | GONCHAROVA, ELENA | reporter.nih.gov |
| Pediatric Cardiopulmonary MRI using RF Navigators and High Dimensional Deep Learning | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,454,963 | July 1, 2024 | March 31, 2029 | JOHNSON, KEVIN MICHAEL | reporter.nih.gov |
| What triggers RV Fiber Re-Orientation in response to RV pressure overload, and what is its Consequence on Inter-Ventricular Decoupling? | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,442,622 | May 1, 2023 | December 31, 2026 | KHEYFETS, VITALY | reporter.nih.gov |
| General Capillary to Arterial Endothelial Cell Transition in Pulmonary ArterialHypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,439,664 | September 15, 2023 | June 30, 2027 | DAI, ZHIYU | reporter.nih.gov |
| Role of Endothelial SOX17 Deficiency in the Pathogenesis of Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $1,429,667 | March 20, 2022 | June 12, 2024 | DAI, ZHIYU | reporter.nih.gov |
| Role of miR125 in pulmonary hypertension secondary to interstitial lung disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,424,682 | December 1, 2019 | November 30, 2024 | EGHBALI, MANSOUREH | reporter.nih.gov |
| Matrikines and COPD-PH | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,416,723 | September 15, 2019 | August 31, 2025 | WELLS, JAMES MICHAEL | reporter.nih.gov |
| The BMP-PPARy Axis and Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,412,935 | April 1, 2008 | April 30, 2025 | RABINOVITCH, MARLENE | reporter.nih.gov |
| Unraveling the systemic manifestations of pulmonary arterial hypertension on lean muscle mass | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,400,604 | September 15, 2024 | June 30, 2029 | AL-NAAMANI, NADINE | reporter.nih.gov |
| Defining how neonatal hyperoxia causes pulmonary hypertension in adults | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,389,146 | December 1, 2023 | November 30, 2027 | O'REILLY, MICHAEL A | reporter.nih.gov |
| Role of HIV gp120 and Nef in Transcriptome Dysregulation and Pulmonary Vascular Remodeling | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,379,736 | December 1, 2023 | November 30, 2027 | ALMODOVAR, SHARILYN | reporter.nih.gov |
| 4D virtual Catheter (4D vCath) for multi-factorial hemodynamics in pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,355,331 | August 1, 2024 | May 31, 2029 | ELBAZ, MOHAMMED | reporter.nih.gov |
| Ion Channels and Membrane Receptors in Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2025 | $1,352,400 | January 15, 2024 | December 31, 2030 | YUAN, JASON X J | reporter.nih.gov |
| Contributions of pulmonary arterial and venous remodeling to HFpEF in the elderly | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,345,416 | May 15, 2022 | April 30, 2027 | SHAH, AMIL M | reporter.nih.gov |
| LDHA-lactate signaling in pulmonary arterial hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,334,993 | December 1, 2023 | November 30, 2027 | GONCHAROVA, ELENA | reporter.nih.gov |
| BMPR2, Monocytes and Macrophages in Pulmonary Artery Hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,325,904 | July 1, 2017 | June 30, 2028 | RABINOVITCH, MARLENE | reporter.nih.gov |
| Interventions Against the Molecular Etiology of BMPR2-induced PAH | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,325,762 | March 1, 2019 | February 28, 2023 | WEST, JAMES D | reporter.nih.gov |
| Systemically restricted 5-HT2B antagonists for pulmonary arterial hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,317,435 | February 1, 2024 | January 31, 2028 | MERRYMAN, WILLIAM D | reporter.nih.gov |
| Anaplerotic reprogramming of endothelial cells in pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,308,953 | August 1, 2016 | May 31, 2027 | RAFIKOV, RUSLAN | reporter.nih.gov |
| Disequilibrium in immune homeostasis in hypoxic pulmonary hypertension pathogenesis | NIH | National Heart, Lung, and Blood Institute | 2025 | $1,286,637 | September 1, 2025 | August 31, 2027 | GONZALEZ BOSC, LAURA V | reporter.nih.gov |
| REHAB-PH Trial: Repurposing a Histamine Antagonist to Benefit Patients with Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,285,203 | September 16, 2018 | July 31, 2024 | LEARY, PETER J | reporter.nih.gov |
| Anaplerotic reprogramming of endothelial cells in pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $1,284,229 | August 1, 2016 | August 4, 2023 | RAFIKOV, RUSLAN | reporter.nih.gov |
| PHORA-Pulmonary Hypertension Outcome Risk Assessment | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $1,268,587 | January 5, 2024 | June 30, 2027 | BENZA, RAYMOND LOUIS | reporter.nih.gov |
| Myocyte Mechanics of Right Ventricular Contractile Failure in Pulmonary Hypertension due to Heart Failure with Reduced Ejection Fraction | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,257,627 | June 1, 2024 | April 30, 2029 | HSU, STEVEN | reporter.nih.gov |
| NOTCH3 ECD as a Serum Biomarker for Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,240,810 | July 15, 2024 | April 30, 2028 | THISTLETHWAITE, PATRICIA A | reporter.nih.gov |
| Phase II Trial of Metformin for Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction | NIH | National Institute on Aging | 2021 to 2022 | $1,234,690 | May 1, 2018 | February 28, 2026 | SIMON, MARC A | reporter.nih.gov |
| Context-specific angiogenic signaling in the pulmonary vasculature | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,229,962 | July 15, 2021 | July 31, 2022 | YU, PAUL B | reporter.nih.gov |
| GENETIC AND DEVELOPMENTAL MECHANISMS OF CONGENITAL DIAPHRAGMATIC HERNIA | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,200,859 | April 17, 2021 | March 31, 2025 | MCCULLEY, DAVID J | reporter.nih.gov |
| Fibroblast Mediated Mechanisms of Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,199,250 | April 15, 2019 | March 31, 2025 | MINSHALL, RICHARD D | reporter.nih.gov |
| Endothelial Reprogramming in Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,168,665 | July 1, 2019 | June 30, 2025 | AL GHOULEH, IMAD | reporter.nih.gov |
| Context-specific angiogenic signaling in the pulmonary vasculature | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $1,166,287 | July 15, 2021 | May 31, 2025 | YU, PAUL B | reporter.nih.gov |
| The Pulmonary Hypertension- Multi-Dimensional Omics to Characterize Right Heart Adaptation (PH-MOCHA) study | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,166,250 | May 1, 2020 | April 30, 2026 | LEARY, PETER J | reporter.nih.gov |
| Targeting FAK-NEDD9 protein-protein interaction to prevent focal adhesion assembly and vascular proliferation in pulmonary arterial hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,147,578 | September 8, 2023 | May 31, 2027 | MARON, BRADLEY | reporter.nih.gov |
| Personalized protein-protein interactomes and precision medicine in pulmonary arterial hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,137,591 | February 1, 2021 | April 30, 2023 | MARON, BRADLEY | reporter.nih.gov |
| Hemolysis and free heme signaling in pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,136,325 | May 1, 2020 | May 31, 2024 | RAFIKOV, RUSLAN | reporter.nih.gov |
| Novel Involvement of eNAMPT/TLR4 Signaling in PAH Vascular Remodeling and Right Ventricular Dysfunction | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,129,998 | February 1, 2019 | June 30, 2029 | GARCIA, JOE G. N. | reporter.nih.gov |
| Role of CXCR2-mediated cell trafficking in pulmonary vascular remodeling | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,127,945 | August 1, 2019 | July 31, 2025 | BRYANT, ANDREW JUSTIN | reporter.nih.gov |
| Fatty acid-binding proteins sustain endothelial glycolysis and arterial programming in pulmonary arterial hypertension | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $1,126,593 | April 15, 2023 | March 31, 2027 | DAI, ZHIYU | reporter.nih.gov |
| Metabolic mechanisms underlying bronchopulmonary dysplasia-associated pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,117,040 | July 1, 2023 | April 30, 2027 | YAO, HONGWEI | reporter.nih.gov |
| Ion Channels and Membrane Receptors in Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 | $1,106,000 | January 15, 2024 | December 31, 2030 | YUAN, JASON X J | reporter.nih.gov |
| Right ventricle remodeling in pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,093,845 | January 1, 2024 | December 31, 2028 | GORR, MATTHEW WILLIAM | reporter.nih.gov |
| Development of novel therapeutic approaches for treatment of Alveolar Capillary Dysplasia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,086,794 | May 1, 2021 | March 3, 2023 | KALINICHENKO, VLADIMIR | reporter.nih.gov |
| The Role of the CES1 in the Pathogenesis of Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,078,528 | August 23, 2024 | May 31, 2028 | DE JESUS PEREZ, VINICIO A | reporter.nih.gov |
| Targeting FAK-NEDD9 protein-protein interaction to prevent focal adhesion assembly and vascular proliferation in pulmonary arterial hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,068,928 | January 1, 2018 | June 6, 2023 | MARON, BRADLEY | reporter.nih.gov |
| Regulation of PDE3 in the Pathobiology of Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,012,887 | March 1, 2018 | December 31, 2024 | CHEN, BERNADETTE | reporter.nih.gov |
| A Digital Hemodynamic Twin for Right Ventricular Dysfunction | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,000,002 | April 8, 2024 | March 31, 2029 | HOUSTIS, NICHOLAS E. | reporter.nih.gov |
| Ventricular-vascular coupling in the elderly: lifecourse determinants, trajectories and prognostic significance | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $990,525 | April 1, 2019 | August 31, 2022 | RAMACHANDRAN, VASAN S | reporter.nih.gov |
| Role of ANO1 Channels and Its Regulation by PIP2 in EC-Coupling in Pulmonary Artery Myocytes | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $987,668 | February 1, 2019 | January 31, 2025 | LEBLANC, NORMAND | reporter.nih.gov |
| 2/2 A Phase 2 Study of Elafin (Tiprelestat) for the Treatment of Pulmonary Arterial Hypertension (PAH) | NIH | National Heart, Lung, and Blood Institute | 2025 | $936,858 | August 15, 2025 | July 31, 2030 | SPINO, CATHERINE A | reporter.nih.gov |
| Novel Mechanisms and Therapeutic Targets for Pulmonary Hypertension in End-Stage Renal Disease (K23) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $921,038 | August 1, 2021 | July 31, 2027 | EDMONSTON, DANIEL | reporter.nih.gov |
| The Roles of Pulmonary Hypertension and Right Ventricular Dysfunction in Pediatric Acute Respiratory Distress Syndrome | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $878,771 | May 1, 2021 | April 30, 2026 | HIMEBAUCH, ADAM S. | reporter.nih.gov |
| 1/2 Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2025 | $873,890 | September 1, 2024 | August 31, 2030 | HERESI DAVILA, GUSTAVO ADOLFO | reporter.nih.gov |
| Role of Mitochondrial c-Src in Right Ventricular Dysfunction in Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $873,719 | May 1, 2024 | February 29, 2028 | ZHANG, PENG | reporter.nih.gov |
| NEDD9-SMAD3, fibrinolysis, and chronic thromboembolic pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $864,664 | June 1, 2020 | May 31, 2024 | MARON, BRADLEY | reporter.nih.gov |
| Administrative Supplement for R01HL166932 | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $851,423 | February 20, 2023 | August 31, 2026 | KUDRYASHOVA, TATIANA V | reporter.nih.gov |
| Understanding the Barriers to Physical Activity in Pediatric Pulmonary Hypertension in Order to Design Effective Home-based Exercise Programs | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $817,946 | August 1, 2021 | June 30, 2027 | AVITABILE, CATHERINE M. | reporter.nih.gov |
| Clinical CT Imaging for Screening and Subtyping of Pulmonary Hypertension in COPD | NIH | National Heart, Lung, and Blood Institute | 2025 | $812,189 | May 1, 2025 | February 28, 2029 | RAHAGHI, FARBOD NICHOLAS | reporter.nih.gov |
| Endothelial Inflammation, Src Kinase Dysregulation, and Fibrosis in Early Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2025 | $800,962 | September 15, 2025 | June 30, 2030 | WERTHEIM, BRADLEY | reporter.nih.gov |
| Generation of Endothelial Cell Memory in Inflammatory Vascular Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $800,077 | August 27, 2021 | July 31, 2026 | DOS SANTOS OLIVEIRA, SUELLEN D'ARC | reporter.nih.gov |
| Role of Endothelial Anoctamin-1 in Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $797,172 | July 1, 2019 | June 30, 2025 | CHOUDHARY, GAURAV | reporter.nih.gov |
| Pulmonary Vascular Disease as a Contributor to Respiratory Morbidity in Chronic Obstructive Pulmonary Disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $793,025 | June 1, 2022 | May 31, 2027 | BALASUBRAMANIAN, APARNA | reporter.nih.gov |
| Mechanistic Roles of Adrenomedullin and its Signaling Receptors in Experimental Bronchopulmonary Dysplasia and Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $792,500 | September 1, 2018 | December 31, 2023 | SHIVANNA, BINOY | reporter.nih.gov |
| Role of Gap Junction in Hypoxia-induced Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $789,792 | May 1, 2019 | April 30, 2024 | MAKINO, AYAKO | reporter.nih.gov |
| ZFP36, an RNA Binding Protein that Regulates DNA Repair and Cell Proliferation in PAH | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $787,500 | July 20, 2024 | May 31, 2028 | EGHBALI, MANSOUREH | reporter.nih.gov |
| Endothelial protocadherins in vascular development and disease | NIH | National Heart, Lung, and Blood Institute | 2025 | $775,720 | August 15, 2025 | May 31, 2029 | SCHWARTZ, MARTIN A | reporter.nih.gov |
| Mitochondrial Fission, Calcium, ROS in Right Ventricular Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $775,000 | July 1, 2023 | June 30, 2027 | JHUN, BONG SOOK | reporter.nih.gov |
| Regulatory T Cells And Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2025 | $773,868 | September 1, 2025 | June 30, 2030 | SHIVANNA, BINOY | reporter.nih.gov |
| The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study | NIH | National Heart, Lung, and Blood Institute | 2022 | $773,113 | September 1, 2022 | August 31, 2023 | BRITTAIN, EVAN L | reporter.nih.gov |
| Insulin Receptor Substrate Signaling in Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $772,500 | December 7, 2017 | November 30, 2023 | KEEGAN, ACHSAH D. | reporter.nih.gov |
| REVAMP-PH: REpurposing Valsartan May Protect against Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2023 | $761,805 | June 1, 2023 | May 31, 2024 | LEARY, PETER J | reporter.nih.gov |
| Alternative polyadenylation in Right Ventricular Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 | $760,708 | September 25, 2024 | September 24, 2025 | AMIRTHALINGAM THANDAVARAYAN, RAJARAJAN | reporter.nih.gov |
| Transbronchial diagnosis and characterization of pulmonary hypertension with Mechanomicroscopy | NIH | National Heart, Lung, and Blood Institute | 2025 | $759,658 | September 1, 2025 | June 30, 2029 | SUTER, MELISSA J | reporter.nih.gov |
| Vascular Smooth Muscle Function in Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $757,500 | February 1, 2013 | April 30, 2025 | JERNIGAN, NIKKI L | reporter.nih.gov |
| Novel Involvement of NAMPT and TLR4 in PAH Vascular Remodeling | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $757,000 | February 1, 2019 | January 5, 2023 | GARCIA, JOE G. N. | reporter.nih.gov |
| Reclassifying Pulmonary Arterial Hypertension Into Immune Phenotypes Using Machine Learning | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $748,224 | June 15, 2020 | May 31, 2025 | SWEATT, ANDREW JOHN | reporter.nih.gov |
| Therapeutic Rescue of a Deficient BMPR2 Hypoxic Response in Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $747,000 | September 1, 2022 | August 31, 2025 | MARCIANO, DAVID P | reporter.nih.gov |
| Master - 2/2 Empaglifozin To Improve Right Ventricular Function in Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $746,327 | September 1, 2024 | August 31, 2030 | GASSMAN, JENNIFER J | reporter.nih.gov |
| PHORA-Pulmonary Hypertension Outcome Risk Assessment | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $741,363 | September 1, 2022 | August 31, 2023 | BENZA, RAYMOND LOUIS | reporter.nih.gov |
| Selective Targeting of Alveolar Capillaries in Neonatal Lung Injury | NIH | National Heart, Lung, and Blood Institute | 2025 | $730,070 | September 1, 2025 | May 31, 2029 | KALINICHENKO, VLADIMIR | reporter.nih.gov |
| Recapitulation of sex- disparity in PAH on a microfluidic device and elucidation of the differences and similarities in the development, progression and therapy of PAH in male versus female patients | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $727,284 | February 1, 2019 | January 31, 2025 | AHSAN, FAKHRUL | reporter.nih.gov |
| Targeting Interleukin-17 inflammatory Axis in CTEPH | NIH | National Heart, Lung, and Blood Institute | 2025 | $723,084 | May 1, 2025 | February 28, 2029 | YU, YEN-REI ANDREA | reporter.nih.gov |
| General Capillary to Arterial Endothelial Cell Transition in Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2023 | $721,701 | September 15, 2023 | June 30, 2024 | DAI, ZHIYU | reporter.nih.gov |
| Epigenetic regulation of pulmonary smooth muscle cell remodeling in Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2023 | $715,161 | September 23, 2023 | August 31, 2025 | SCHWARZ, MARGARET A | reporter.nih.gov |
| Mitochondrial Dysfunction in Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $708,886 | August 25, 2022 | August 4, 2023 | RAFIKOVA, OLGA | reporter.nih.gov |
| The role of xanthine oxidoreductase activity and altered metabolism in scleroderma-associated pulmonary arterial hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $706,320 | August 15, 2020 | July 31, 2025 | SIMPSON, CATHERINE | reporter.nih.gov |
| Pulmonary vascular glutamine metabolism at the intersection of hemodynamic forces and smooth muscle proliferation in congenital heart disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $699,192 | August 15, 2020 | July 31, 2025 | BOEHME, JASON | reporter.nih.gov |
| Pulmonary Artery Endothelial Cell Endotypes and the Role of Anoikis Resistance in Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2025 | $692,768 | March 1, 2025 | December 31, 2028 | VENTETUOLO, COREY E | reporter.nih.gov |
| MRI Metrics of Diastolic Dysfunction at Rest and Stress Validated by Estimated Pressures | NIH | National Heart, Lung, and Blood Institute | 2024 | $690,669 | January 1, 2019 | August 31, 2026 | PETERS, DANA C | reporter.nih.gov |
| Imaging of pulmonary arterial hypertension with proton MRI | NIH | National Heart, Lung, and Blood Institute | 2022 | $683,976 | September 22, 2022 | August 31, 2025 | HOPKINS, SUSAN R | reporter.nih.gov |
| Ubiquitination and Endothelial Fibrosis in Early Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $675,715 | July 1, 2020 | June 30, 2025 | WERTHEIM, BRADLEY | reporter.nih.gov |
| The Development of a Biatrial Catheter for a Cardiopulmonary Support System in Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $671,968 | September 15, 2023 | July 31, 2026 | BENZA, RAYMOND LOUIS | reporter.nih.gov |
| The protective role of fibroblast growth factor signaling in hypoxia-induced pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $660,564 | September 20, 2022 | August 31, 2027 | WOO, KELVIN | reporter.nih.gov |
| Targeting response gene to complement 32 to alleviate vascular remodeling | NIH | National Heart, Lung, and Blood Institute | 2025 | $658,885 | January 1, 2025 | November 30, 2028 | CHEN, SHIYOU | reporter.nih.gov |
| Metabolic mechanisms underlying bronchopulmonary dysplasia-associated pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2023 | $657,427 | July 1, 2023 | February 29, 2024 | YAO, HONGWEI | reporter.nih.gov |
| CXCL12 signaling axis in pulmonary arterial heterogeneity, development, and disease | NIH | National Heart, Lung, and Blood Institute | 2023 | $657,308 | September 12, 2023 | August 31, 2025 | FRANK, DAVID BRIAN | reporter.nih.gov |
| Defining the Role of ROR2 in Right Ventricular Failure Pathogenesis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $657,000 | August 10, 2021 | July 31, 2026 | EDWARDS, JONATHAN JOSEPH | reporter.nih.gov |
| Role of Vitamin D in Lung Development and Bronchopulmonary Dysplasia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $647,596 | February 15, 2020 | January 31, 2026 | MANDELL, ERICA WYNNE | reporter.nih.gov |
| Role of right ventricular passive remodeling in ventricular-arterial uncoupling in pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 | $642,045 | September 20, 2024 | August 31, 2025 | AVAZMOHAMMADI, REZA | reporter.nih.gov |
| Activation Mechanism of Soluble Guanylate Cyclase | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $638,990 | March 1, 2019 | December 31, 2022 | MARLETTA, MICHAEL A. | reporter.nih.gov |
| Pulmonary Hypertension-Associated Pediatric Cardiac Arrest | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $631,700 | April 1, 2020 | March 31, 2026 | MORGAN, RYAN WILLIAM | reporter.nih.gov |
| Biomarker Discovery in Portopulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $618,300 | April 21, 2023 | March 31, 2028 | JOSE, ARUN | reporter.nih.gov |
| TGF-β signaling and regulation: Elucidating molecular mechanisms and pathogenic functions of the ‘co-receptor’ Cripto-1 and the receptor BMPRII | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $610,107 | January 1, 2018 | December 31, 2023 | MARTINEZ HACKERT, ERIK MATTHIAS | reporter.nih.gov |
| Role of endothelial Twist1 in vascular remodeling in pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $608,252 | February 1, 2019 | January 31, 2025 | MAMMOTO, AKIKO | reporter.nih.gov |
| Diverse effects of hemin on the endothelium contribute to pulmonary complications of sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2024 | $607,535 | September 17, 2024 | August 31, 2025 | FRAIDENBURG, DUSTIN | reporter.nih.gov |
| Targeting mitoNEET in pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2025 | $596,809 | June 1, 2025 | March 31, 2029 | HART, C MICHAEL | reporter.nih.gov |
| Role of ER-mitochondria contact sites in Right Ventricular Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 | $587,749 | July 1, 2024 | April 30, 2028 | O-UCHI, JIN | reporter.nih.gov |
| Pulmonary Vascular Pruning on Computed Tomography and Interstitial Lung Disease Outcomes | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $573,856 | April 5, 2023 | February 29, 2028 | SYNN, ANDREW | reporter.nih.gov |
| Fatty acid-binding proteins sustain endothelial glycolysis and arterial programming in pulmonary arterial hypertension | NIH | National Heart, Lung, and Blood Institute | 2025 | $569,497 | April 15, 2023 | March 31, 2027 | DAI, ZHIYU | reporter.nih.gov |
| Role of ER-mitochondria contact sites in Right Ventricular Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2025 | $565,763 | July 1, 2024 | April 30, 2028 | O-UCHI, JIN | reporter.nih.gov |
| Hemodynamic Contributions to Vascular Dysfunction in Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $560,368 | April 15, 2023 | March 31, 2028 | RAYNER, SAMUEL GIBSON | reporter.nih.gov |
| MhOVE-PPH Study: Mobile health interventiOn to improVe Exercise in Pediatric PH | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $553,802 | May 1, 2024 | April 30, 2027 | AUSTIN, ERIC DOUGLAS | reporter.nih.gov |
| Phase-1 Healthy adult human safety and pharmacokinetic study of AVR-48, a small molecule macrophage modulator to prevent bronchopulmonary dysplasia in at-risk pre-term infants | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $550,576 | May 1, 2023 | April 30, 2025 | ACHARYA, SUCHISMITA | reporter.nih.gov |
| Novel Computational Framework for Free-Breathing & Ungated Dynamic MRI | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 | $550,567 | April 1, 2016 | July 31, 2024 | JACOB, MATHEWS | reporter.nih.gov |
| Novel Computational Framework for Free-Breathing & Ungated Dynamic MRI | NIH | National Institute of Biomedical Imaging and Bioengineering | 2024 to 2025 | $548,957 | April 1, 2016 | July 31, 2028 | JACOB, MATHEWS | reporter.nih.gov |
| PHORA-Pulmonary Hypertension Outcome Risk Assessment | NIH | National Heart, Lung, and Blood Institute | 2025 | $543,703 | January 5, 2024 | June 30, 2027 | BENZA, RAYMOND LOUIS | reporter.nih.gov |
| Therapeutic activation of AMPK for the aging right heart | NIH | National Institute on Aging | 2021 to 2023 | $540,806 | March 1, 2019 | November 30, 2024 | BRUNS, DANIELLE REULAND | reporter.nih.gov |
| Bioenergetic impairment in Group 3 pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $534,600 | September 1, 2023 | August 31, 2028 | TRAMMELL, AARON WAYNE | reporter.nih.gov |
| Mechanisms and treatment of right ventricular sarcomere dysfunction in scleroderma-associated pulmonary arterial hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $531,360 | April 1, 2019 | March 31, 2024 | HSU, STEVEN | reporter.nih.gov |
| Integrative Multiomics to Uncover Novel Genes and Networks in Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $529,740 | August 10, 2023 | July 31, 2028 | HONG, JASON | reporter.nih.gov |
| Novel Role of Classical Dendritic Cells in the pathogenesis of Hypoxia-Induced Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $529,196 | September 1, 2022 | August 31, 2027 | MICKAEL, CLAUDIA SILVA | reporter.nih.gov |
| Role of the Novel MicroRNA-125b in Pulmonary Hypertension Associated with Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $527,472 | May 1, 2019 | April 30, 2024 | UMAR, SOBAN | reporter.nih.gov |
| Hv1 in Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2025 | $522,794 | June 1, 2025 | March 31, 2029 | HONG, LIANG | reporter.nih.gov |
| The Role of Placental Maternal Vascular Underperfusion in Neonatal Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 | $517,030 | February 15, 2018 | January 31, 2024 | MESTAN, KAREN K | reporter.nih.gov |
| The Therapeutic Role for LOLX2 in Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $515,160 | January 1, 2019 | December 31, 2023 | STEPPAN, JOCHEN | reporter.nih.gov |
| The role of kynurenine pathway metabolism in pulmonary arterial hypertension | NIH | National Heart, Lung, and Blood Institute | 2025 | $514,484 | August 24, 2025 | June 30, 2030 | SIMPSON, CATHERINE | reporter.nih.gov |
| Type I interferon regulates angiogenesis in Down Syndrome Supplement | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $507,399 | September 6, 2022 | January 31, 2025 | AL-ALAM, DENISE | reporter.nih.gov |
| The contribution of hypoxia inducible factor-1-dependent glycolysis in lung interstitial macrophages to the pathobiology of schistosomiasis-induced pulmonary hypertension. | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $507,060 | April 5, 2023 | March 31, 2028 | LEE, MICHAEL HYUNJEAN | reporter.nih.gov |
| Personalized protein-protein interactomes and precision medicine in pulmonary arterial hypertension | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $503,343 | February 1, 2021 | January 31, 2026 | MARON, BRADLEY | reporter.nih.gov |
| Peripheral Limitations in Pulmonary Hypertension and Effects of Muscle Training | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $503,231 | April 10, 2023 | March 31, 2028 | REDDY, YOGESH NELLORE VILAMBI | reporter.nih.gov |
| Uncovering compensatory mechanisms in family members with disease causing mutations of pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $498,000 | August 15, 2020 | July 31, 2023 | GU, MINGXIA | reporter.nih.gov |
| Neuroimmune axis contribution to the pathophysiology of pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $498,000 | July 15, 2024 | June 30, 2027 | OLIVEIRA, ALINE CRISTINA | reporter.nih.gov |
| RNA editing controls pulmonary endothelial pathophenotypes in pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $498,000 | September 1, 2024 | August 31, 2027 | WOODCOCK, CHEN-SHAN JULIA | reporter.nih.gov |
| Deep Learning Assessment of the Right Ventricle: Function, Etiology, and Prognosis | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $497,958 | February 1, 2023 | January 31, 2025 | OUYANG, DAVID | reporter.nih.gov |
| Multimeric prodrugs for pulmonary hypertension therapy | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $484,000 | September 1, 2021 | August 31, 2024 | CHORNY, MICHAEL | reporter.nih.gov |
| MENTORED PATIENT-ORIENTED RESEARCH TOWARDS OPTIMIZING CARDIOVASCULAR OUTCOMES IN CHRONIC KIDNEY DISEASE | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $471,078 | July 15, 2022 | June 30, 2027 | NAVANEETHAN, SANKAR DASS | reporter.nih.gov |
| Screening for schistosomiasis-associated pulmonary arterial hypertension | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $464,950 | August 15, 2023 | July 31, 2025 | HILTON, JOAN F | reporter.nih.gov |
| Mentorship in Pulmonary Vascular Disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $458,576 | January 1, 2022 | December 31, 2026 | HEMNES, ANNA R | reporter.nih.gov |
| Sildenafil to Reduce Vascular Remodeling during Left Ventricular Assist Device Support | NIH | National Heart, Lung, and Blood Institute | 2025 | $455,826 | January 1, 2025 | December 31, 2029 | SAEED, OMAR | reporter.nih.gov |
| Identifying novel clinical, genetic and proteomic risk factors for sickle cell nephropathy. | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $442,750 | April 15, 2021 | March 31, 2023 | ASHLEY-KOCH, ALLISON E | reporter.nih.gov |
| Role of Endothelial SOX17 Deficiency in the Pathogenesis of Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2025 | $437,404 | March 20, 2022 | February 28, 2027 | DAI, ZHIYU | reporter.nih.gov |
| 1/2 Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 | $433,123 | September 1, 2024 | August 31, 2025 | HERESI DAVILA, GUSTAVO ADOLFO | reporter.nih.gov |
| A novel microfluidic platform to study exosome biology in PAH. | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $433,113 | March 25, 2021 | February 28, 2023 | DEMIRCI, UTKAN | reporter.nih.gov |
| A growth-accommodating transcatheter pulmonary valve system for young children | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $431,750 | July 7, 2021 | June 30, 2024 | KHERADVAR, ARASH | reporter.nih.gov |
| Abnormal HIF signaling in Down syndrome-related pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $427,625 | September 6, 2022 | July 31, 2024 | GALAMBOS, CSABA | reporter.nih.gov |
| PAH-on-a-chip: a novel disease-on-a-device model for studying the pathobiology of and screening drugs for pulmonary arterial hypertension | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $426,671 | July 1, 2023 | June 30, 2025 | AHSAN, FAKHRUL | reporter.nih.gov |
| Novel non-invasive approach for predicting retinopathy of prematurity in premature neonates | NIH | National Eye Institute | 2023 to 2024 | $426,250 | September 30, 2023 | August 31, 2025 | DE PLAEN, ISABELLE G | reporter.nih.gov |
| HIPK2 signaling in Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2023 | $414,969 | February 20, 2023 | May 31, 2023 | KUDRYASHOVA, TATIANA V | reporter.nih.gov |
| Non-invasive measurements of central blood pressures by RF sensors | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 to 2024 | $407,391 | August 1, 2023 | July 31, 2025 | KAN, EDWIN C | reporter.nih.gov |
| Role of SIN3a in the epigenetic regulation of the Bone Morphogenetic Protein Receptor Type 2 in pulmonary arterial hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $405,909 | September 1, 2022 | August 31, 2025 | BISSERIER, MALIK | reporter.nih.gov |
| Obesity in Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $387,257 | June 10, 2018 | May 31, 2024 | AL-NAAMANI, NADINE | reporter.nih.gov |
| Physical activity phenotypes and their association with traditional outcomes in pulmonary arterial hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $382,162 | July 1, 2024 | June 30, 2029 | MINHAS, JASLEEN | reporter.nih.gov |
| Mitochondrial Fission, Calcium, ROS in Right Ventricular Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2025 | $375,000 | July 1, 2023 | June 30, 2027 | JHUN, BONG SOOK | reporter.nih.gov |
| Structural and Funcional Vascular Phenotyping in Smokers with Pulmonary Hypertension using Artificial Intelligence | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $374,160 | December 1, 2023 | November 30, 2028 | NARDELLI, PIETRO | reporter.nih.gov |
| Profiling circulating metabolites for the diagnosis of pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 | $373,684 | April 1, 2022 | March 31, 2024 | RAFIKOVA, OLGA | reporter.nih.gov |
| Modulating the Microbiome to Enhance Right Ventricular Function in Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $350,136 | December 8, 2023 | November 30, 2028 | PRISCO, SASHA ZHENG | reporter.nih.gov |
| An early-intervention gene-editing therapeutic for Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2023 | $350,000 | September 1, 2023 | August 31, 2024 | JASKULA-RANGA, VINOD | reporter.nih.gov |
| Eicosanoid Pathways Underlying Disease Risk in Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $348,192 | January 1, 2024 | December 31, 2028 | ALOTAIBI, MONA A | reporter.nih.gov |
| Salivary miRNAs as Prognostic Markers of Pulmonary Hypertension Associated with Bronchopulmonary Dysplasia in Extremely Low Gestational Age Infants | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2024 | $347,238 | August 1, 2023 | July 31, 2028 | SIDDAIAH, ROOPA | reporter.nih.gov |
| IL17 mediates chorioamnionitis induced lung damage | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $342,190 | August 15, 2024 | July 31, 2029 | JAIN, VIRAL G | reporter.nih.gov |
| Advanced CMR Tissue-Based Prediction of Right Ventricular Dysfunction and Revascularization Response | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $338,486 | December 15, 2017 | November 30, 2023 | KIM, JIWON | reporter.nih.gov |
| Regulation of UPRmt activation in the development of pulmonary vascular remodeling in PAH | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $336,480 | August 1, 2022 | July 31, 2025 | LOCKETT, ANGELIA DENISE | reporter.nih.gov |
| The Development of a Biatrial Catheter for a Cardiopulmonary Support System in Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2023 | $335,984 | September 15, 2023 | July 31, 2024 | BENZA, RAYMOND LOUIS | reporter.nih.gov |
| Endothelial cell-based therapy for pulmonary vascular disease using induced pluripotent stem cells | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $335,880 | April 20, 2024 | March 31, 2029 | HOLTZ, ALEXANDER MATTHEW | reporter.nih.gov |
| Age-related Changes in the Pulmonary Artery | NIH | National Institute on Aging | 2022 to 2023 | $335,000 | September 1, 2022 | May 31, 2026 | MANNING, EDWARD P | reporter.nih.gov |
| Mural cells contribution to vascular remodeling in flow induced pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $332,843 | September 20, 2024 | August 31, 2029 | KLOUDA, TIMOTHY | reporter.nih.gov |
| Exploiting neointimal and vascular smooth muscle cell heterogeneity to reveal mechanisms driving venous neointimal growth and vascular remodeling in pediatric pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $331,227 | May 5, 2024 | April 30, 2029 | STEFFES, LEA | reporter.nih.gov |
| Role of mTOR Hyperactivation in Pulmonary Vascular Remodeling | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $329,400 | August 15, 2024 | July 31, 2029 | LIN, SUSAN M | reporter.nih.gov |
| Mechanisms of right ventricular dysfunction in type 2 diabetes | NIH | National Heart, Lung, and Blood Institute | 2024 | $323,277 | September 25, 2024 | August 31, 2025 | BRUNS, DANIELLE REULAND | reporter.nih.gov |
| Post-GWAS Functional Genomics Analysis to Define Pathogenic Mechanisms for Pulmonary ArterialHypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $321,602 | September 1, 2024 | August 31, 2027 | SUN, WEI | reporter.nih.gov |
| Post-GWAS Functional Genomics Analysis to Define Pathogenic Mechanisms for Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $321,442 | September 15, 2022 | March 31, 2024 | SUN, WEI | reporter.nih.gov |
| Therapeutic Strategies for the Management of Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $321,290 | December 5, 2024 | July 31, 2029 | GENTLE, SAMUEL J | reporter.nih.gov |
| A Pathogenic Role for Natriuretic Peptide Receptor-C in Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $316,872 | August 10, 2021 | July 31, 2026 | AGRAWAL, VINEET | reporter.nih.gov |
| Deep Learning Assessment of the Right Ventricle: Function, Etiology, and Prognosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $313,393 | April 1, 2021 | January 31, 2023 | OUYANG, DAVID | reporter.nih.gov |
| Recognition of O-GlcNAc Modified Proteins Using Site-Specific Antibodies | NIH | National Heart, Lung, and Blood Institute | 2023 | $275,767 | June 15, 2023 | May 31, 2025 | POPOV, MARLA | reporter.nih.gov |
| Mechanisms of Junctophilin-2 Misregulation that contribute to right ventricular dysfunction in pulmonary arterial hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $270,594 | July 1, 2018 | June 30, 2023 | PRINS, KURT W | reporter.nih.gov |
| Neuroimmune axis contribution to the pathophysiology of pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $266,220 | April 1, 2023 | July 14, 2024 | OLIVEIRA, ALINE CRISTINA | reporter.nih.gov |
| Endothelial Proline Utilization in Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $262,970 | August 1, 2024 | July 31, 2027 | WERTHEIM, BRADLEY | reporter.nih.gov |
| Aminopeptidase N Driven Signaling in the Development of Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2025 | $249,000 | August 1, 2025 | June 30, 2028 | JAMES, JOEL | reporter.nih.gov |
| Deep Learning Assessment of the Right Ventricle: Function, Etiology, and Prognosis | NIH | National Heart, Lung, and Blood Institute | 2025 | $248,979 | April 15, 2025 | January 31, 2027 | OUYANG, DAVID | reporter.nih.gov |
| Unsupervised Machine Learning to Identify Unique Clusters of Systemic Sclerosis Pulmonary Hypertension Patients | NIH | National Heart, Lung, and Blood Institute | 2025 | $245,624 | September 5, 2025 | August 31, 2027 | LAMMI, MATTHEW R | reporter.nih.gov |
| Vascular Smooth Muscle Vps34 in Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2025 | $244,589 | May 20, 2025 | April 30, 2028 | SHEN, YUANJUN | reporter.nih.gov |
| Isolated Abnormality in the Diffusion Capacity for Carbon Monoxide in People Living with HIV – Epidemiology, Etiology and Pathogenesis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $240,190 | September 1, 2022 | June 30, 2025 | BYANOVA, KATERINA L. | reporter.nih.gov |
| Vascular Smooth Muscle Vps34 in Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $224,886 | April 10, 2023 | March 31, 2025 | SHEN, YUANJUN | reporter.nih.gov |
| RNA editing controls pulmonary endothelial pathophenotypes in pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $212,016 | September 10, 2022 | August 31, 2024 | WOODCOCK, CHEN-SHAN JULIA | reporter.nih.gov |
| Right Ventricular Remodeling in Tetralogy of Fallot | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $206,439 | August 1, 2022 | July 31, 2027 | THOMPSON, ELIZABETH WALKER | reporter.nih.gov |
| Aminopeptidase N Driven Signaling in the Development of Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $204,806 | May 1, 2024 | July 31, 2025 | JAMES, JOEL | reporter.nih.gov |
| Identifying Clinical Markers of Right Ventricular Adaptation to Improve Survival Predictions in Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $193,896 | September 10, 2024 | September 9, 2026 | ROSEN, DARIN | reporter.nih.gov |
| Right Ventricular Response to Exercise Among Patients with Chronic Obstructive Pulmonary Disease | NIH | National Heart, Lung, and Blood Institute | 2025 | $190,825 | August 1, 2025 | May 1, 2030 | FORBES, LINDSAY M | reporter.nih.gov |
| Distinguishing Phenotypes of Pulmonary Hypertension in Patients with Connective Tissue Disease-related Interstitial Lung Disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $184,568 | September 1, 2023 | June 30, 2025 | KHAN, SARAH | reporter.nih.gov |
| Proteomic Signatures Associated with Right Ventricular Failure and Mortality in Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $176,416 | July 1, 2023 | June 30, 2025 | PI, HONGYANG | reporter.nih.gov |
| Multi-Omics Approaches for the Diagnosis and Risk Stratification of Pulmonary Fibrosis-Associated Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2025 | $175,392 | August 1, 2025 | July 31, 2030 | BROWNSTEIN, ADAM JOSEPH | reporter.nih.gov |
| FLI1 in Pulmonary Arterial Hypertension | NIH | National Center for Advancing Translational Sciences | 2023 | $175,000 | August 1, 2023 | July 31, 2024 | HEMNES, ANNA R | reporter.nih.gov |
| UAB Mentoring Program in COPD Patient Oriented Research | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $172,374 | January 15, 2018 | December 31, 2023 | DRANSFIELD, MARK T | reporter.nih.gov |
| Computed tomography for early detection and phenotyping of pulmonary hypertension associated with chronic obstructive pulmonary disease with implications for treatment | NIH | National Heart, Lung, and Blood Institute | 2025 | $171,858 | August 1, 2025 | July 31, 2030 | JOHNSON, SHELSEY WEINSTEIN | reporter.nih.gov |
| The role of extracellular cAMP in the pathogenesis of pulmonary arterial hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 | $170,640 | March 20, 2018 | February 29, 2024 | SASSI, YASSINE | reporter.nih.gov |
| A novel mechanism regulating apoptosis in pulmonary arterial smooth muscle cells | NIH | National Heart, Lung, and Blood Institute | 2025 | $170,640 | September 19, 2025 | August 31, 2030 | NIEDERMEYER, SHANNON | reporter.nih.gov |
| Targeting mitochondria-derived reactive oxygen species as a therapy for combined pre- and post-capillary pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $170,538 | December 1, 2022 | November 30, 2024 | TRIANTAFYLLOU, GEORGIOS | reporter.nih.gov |
| ARID1a and Chromatin Landscape in Pulmonary Vascular Disease | NIH | National Center for Advancing Translational Sciences | 2023 | $169,000 | September 1, 2023 | August 31, 2025 | HADRI, LAHOUARIA | reporter.nih.gov |
| OPTImal vasoPRESsor in persistent pulmonary hypertension of the newborn (OPTIPRES) | NIH | National Heart, Lung, and Blood Institute | 2025 | $164,916 | August 1, 2025 | July 31, 2030 | SANKARAN, DEEPIKA | reporter.nih.gov |
| Sex Differences in Cardiac Macrophages in Response to Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2025 | $163,145 | September 1, 2025 | August 31, 2030 | GU, SUE | reporter.nih.gov |
| ACTN4 Binding to Functional SNP rs9277336 Controls the Genome Architecture and Endothelial Pathophenotypes in Pulmonary Arterial | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $161,206 | September 26, 2023 | March 25, 2027 | KIRILLOVA, ANNA | reporter.nih.gov |
| Salivary miRNAs as Prognostic Markers of Pulmonary Hypertension Associated with Bronchopulmonary Dysplasia in Extremely Low Gestational Age Infants | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2025 | $159,422 | August 1, 2023 | July 31, 2028 | SIDDAIAH, ROOPA | reporter.nih.gov |
| RASA3 is a Candidate Gene in the Pathogenesis of Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2025 | $156,416 | August 22, 2025 | July 31, 2030 | PROHASKA, CLARE | reporter.nih.gov |
| Sine Oculis Homeobox Homolog 1 and clusterin in Pulmonary Hypertension associated with Systemic Sclerosis | NIH | National Center for Advancing Translational Sciences | 2025 | $156,000 | June 16, 2025 | December 15, 2026 | KARMOUTY-QUINTANA, HARRY | reporter.nih.gov |
| Macrophage-specific Pair Immunoglobulin-like Type 2 Receptor beta (PILRB) regulation of Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $155,500 | September 21, 2021 | August 31, 2024 | YU, YEN-REI ANDREA | reporter.nih.gov |
| Mechanisms Driving Apoptosis Resistance in Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $154,333 | August 1, 2022 | July 1, 2024 | NIEDERMEYER, SHANNON | reporter.nih.gov |
| Airborne particulates exacerbate vascular remodeling in pulmonary hypertension | NIH | National Institute of Environmental Health Sciences | 2025 | $149,857 | July 7, 2025 | June 30, 2030 | KELLY, NEIL JEREMIAH | reporter.nih.gov |
| E-cigarette Inhalation and Cardiopulmonary Dysfunction | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $131,182 | January 2, 2022 | May 15, 2025 | WHITEHEAD, ANNA KATHRYN | reporter.nih.gov |
| Lipidomics of Pulmonary Vascular Disease | NIH | National Heart, Lung, and Blood Institute | 2025 | $122,813 | February 1, 2025 | January 31, 2027 | SIMPSON, CATHERINE | reporter.nih.gov |
| Secondary Analysis of 3D Echo Images of the Right Ventricle to Compute 3D Surface Strain | NIH | National Heart, Lung, and Blood Institute | 2025 | $117,000 | March 10, 2025 | December 31, 2026 | HUNTER, KENDALL STEPHEN | reporter.nih.gov |
| Defining the Role of of Noncanonical GPCR Signalling in Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $113,299 | May 1, 2021 | April 30, 2024 | LEE, CLAUDIA Y | reporter.nih.gov |
| Targeting Macrophage Populations to Attenuate Pulmonary Hypertension Associated with Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2025 | $111,626 | August 1, 2025 | July 31, 2027 | LISK, CHRISTINA | reporter.nih.gov |
| Engineering Dynamic 3D-Bioprinted Models of Pulmonary Vascular Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $97,954 | February 1, 2021 | July 15, 2023 | DAVIS-HALL, DUNCAN J | reporter.nih.gov |
| High spatial resolution evaluation of subclinical regions of myocardial dysfunction in adult patients with tetralogy of Fallot | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $82,658 | September 1, 2023 | August 31, 2025 | CRAINE, AMANDA | reporter.nih.gov |
| Novel mechanism for eNAMPT secretion in PAH vascular remodeling | NIH | National Institute on Aging | 2023 to 2024 | $82,159 | August 21, 2023 | August 20, 2025 | RODRIGUEZ, MARISELA | reporter.nih.gov |
| Effect of right-ventricular structural remodeling during pressure overload on the mechanical behavior of myofibers in excised human myocardium | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $81,686 | September 1, 2021 | September 30, 2022 | CORMACK, JOHN | reporter.nih.gov |
| Endothelial NOX1-Mediated AMPKa1 Propagates Hypoxia-Induced Pulmonary Hypertension via the CIP/KIP family of CDK inhibitors | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $81,592 | February 1, 2024 | July 31, 2025 | GOOSSEN, CHRISTIAN J | reporter.nih.gov |
| Novel methods to sub-phenotype patients with pulmonary hypertension due to chronic lung disease with implications for treatment | NIH | National Heart, Lung, and Blood Institute | 2022 | $80,746 | July 1, 2022 | June 30, 2023 | JOHNSON, SHELSEY WEINSTEIN | reporter.nih.gov |
| Quantitative framework to predict CTEPH surgical outcome from imaging | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $80,262 | January 23, 2022 | January 22, 2024 | BIRD, ELIZABETH M. | reporter.nih.gov |
| Mechanisms of HIF-Induced Microvascular Endothelial Dysfunction in Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 | $77,039 | July 1, 2021 | June 30, 2023 | BELECANECH, RYAN | reporter.nih.gov |
| Role for Nrf2 and exercise in mitigating pulmonary hypertension-induced vascular dysfunction | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $72,564 | September 1, 2023 | August 31, 2026 | SCHULZE, KIANA MARIE | reporter.nih.gov |
| Mechanisms of Large Animal RV Dysfunction | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $71,210 | September 30, 2024 | September 29, 2026 | MENDELSON, JENNA BLAIR | reporter.nih.gov |
| Extracellular redox biology links to metabolic and mitochondrial dysfunction in pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2023 | $69,114 | September 2, 2023 | June 30, 2024 | COLON HIDALGO, DANIEL ANTONIO | reporter.nih.gov |
| Investigation of a Right Ventricle Based Decellularized Extracellular Matrix Hydrogel and Cardiac Progenitor Cells as a Treatment for Right Ventricular Heart Failure | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $62,664 | March 1, 2022 | September 25, 2023 | HUNTER, JERVAUGHN D | reporter.nih.gov |
| The Role of Mitochondrial Acid-Sensing Ion Channel 1 in Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $62,307 | September 1, 2024 | February 28, 2026 | TUINEAU, MEGAN | reporter.nih.gov |
| Novel Biomarkers of Right Ventricular Dysfunction in Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 | $57,184 | September 20, 2022 | June 30, 2023 | NARANJO TOVAR, MARIO | reporter.nih.gov |
| Cholesterol Regulation of EGFR-dependent Vasoconstriction in Chronic Hypoxia-induced Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $49,025 | February 1, 2022 | May 12, 2023 | AHMADIAN, ROSSTIN | reporter.nih.gov |
| Impact of Sleep Disturbance and Circadian Disruption on Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2025 | $44,065 | July 15, 2025 | IMANI, SEUN IDOWU | reporter.nih.gov | |
| A novel mouse model of Pulmonary Hypertension due to systemic Endothelial Cell Dysfunction | NIH | National Heart, Lung, and Blood Institute | 2023 | $43,102 | March 1, 2024 | August 31, 2024 | KLOUDA, TIMOTHY | reporter.nih.gov |
| PROTECTIVE POISON AT HIGH ALTITUDE: THERAPEUTIC EFFECTS OF ELEVATED ENDOGENOUS CO FROM ADAPTIVE HMOX2 VARIANTS | NIH | National Heart, Lung, and Blood Institute | 2025 | $42,596 | April 1, 2025 | March 31, 2027 | KONG, MITCHELL CHUNG-HIN | reporter.nih.gov |
| Role of cell-specific durotaxis in pulmonary arterial hypertension pathogenesis | NIH | National Heart, Lung, and Blood Institute | 2025 | $41,807 | December 1, 2025 | November 30, 2028 | ISLAM, TAMANNA | reporter.nih.gov |
| The Role of Smooth Muscle Cell Fatty Acid Oxidation in the Pathogenesis of Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 | $39,274 | August 17, 2020 | August 16, 2022 | LEE, MICHAEL HYUNJEAN | reporter.nih.gov |
| Advanced Right Ventricular Functional Analysis for Right Ventricular Failure Risk in Pre-Implant Left Ventricular Assist Device Patients | NIH | National Heart, Lung, and Blood Institute | 2022 | $25,654 | September 1, 2022 | March 31, 2023 | SCOTT, ANDERSON | reporter.nih.gov |
| Pulmonary Endothelial-Mesenchymal Crosstalk in Hyperactive mTOR Lung Diseases | NIH | National Heart, Lung, and Blood Institute | 2022 | $24,957 | January 1, 2022 | April 30, 2022 | LIN, SUSAN M | reporter.nih.gov |
| Pulmonary Hypertension: State of the Art and Therapeutic Opportunities | NIH | National Heart, Lung, and Blood Institute | 2023 | $15,300 | April 1, 2023 | March 31, 2024 | SHEPPARD, TERRY L. | reporter.nih.gov |
| 2023 Grover Conference | NIH | National Heart, Lung, and Blood Institute | 2023 | $10,000 | August 1, 2023 | July 31, 2024 | HEMNES, ANNA R | reporter.nih.gov |
| Therapeutic Strategies for the Management of Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 | $10,000 | August 6, 2024 | September 17, 2024 | GENTLE, SAMUEL J | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Stanford University | Stanford, CA | 15 | $26.8 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 21 | $24.1 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 16 | $22.7 million | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 13 | $20.9 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 14 | $20.2 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 15 | $19.5 million | 0 | $0 |
| Duke University | Durham, NC | 7 | $16.7 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 14 | $14.3 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 9 | $14.1 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 10 | $13.1 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 4 | $12.2 million | 0 | $0 |
| University of Arizona | Tucson, AZ | 10 | $11.7 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 9 | $11.2 million | 0 | $0 |
| Cincinnati Childrens Hosp Med CTR | Cincinnati, OH | 6 | $11.1 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 15 | $10.8 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 4 | $8.8 million | 0 | $0 |
| Yale University | New Haven, CT | 5 | $7.1 million | 0 | $0 |
| Augusta University | Augusta, GA | 3 | $7 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 7 | $6.5 million | 0 | $0 |
| University of Florida | Gainesville, FL | 7 | $6 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 5 | $5.9 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 6 | $5.8 million | 0 | $0 |
| University of California at Davis | Davis, CA | 5 | $5.8 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 3 | $5.7 million | 0 | $0 |
| Lurie Children's Hospital of Chicago | Chicago, IL | 3 | $5.6 million | 0 | $0 |
| University of Washington | Seattle, WA | 6 | $5.5 million | 0 | $0 |
| Loma Linda University | Loma Linda, CA | 2 | $5.4 million | 0 | $0 |
| Washington University | Saint Louis, MO | 5 | $5.3 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 2 | $5 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 4 | $4.7 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 5 | $4.5 million | 0 | $0 |
| Minnesota Healthsolutions Corporation | Saint Paul, MN | 2 | $4.5 million | 0 | $0 |
| Cleveland Clinic Lerner Com-Cwru | Cleveland, OH | 4 | $4.3 million | 0 | $0 |
| Children's Hosp of Philadelphia | Philadelphia, PA | 6 | $4.1 million | 0 | $0 |
| University of New Mexico Health Scis CTR | Albuquerque, NM | 5 | $3.9 million | 0 | $0 |
| Rhode Island Hospital | Providence, RI | 3 | $3.8 million | 0 | $0 |
| Vanderbilt University | Nashville, TN | 2 | $3.8 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 2 | $3.8 million | 0 | $0 |
| Ohio State University | Columbus, OH | 3 | $3.6 million | 0 | $0 |
| University of Texas at Austin | Austin, TX | 1 | $3.5 million | 0 | $0 |
| University of Rochester | Rochester, NY | 2 | $3.1 million | 0 | $0 |
| University of Illinois at Chicago | Chicago, IL | 4 | $3.1 million | 0 | $0 |
| Mti Biotech, Inc. | Ames, IA | 1 | $3.1 million | 0 | $0 |
| Halo Biosciences, Inc. | Palo Alto, CA | 1 | $3 million | 0 | $0 |
| Boston University Medical Campus | Boston, MA | 3 | $3 million | 0 | $0 |
| Inovodel, Inc. | Bethany Beach, DE | 1 | $2.9 million | 0 | $0 |
| Translational Sciences, Inc. | Paradise Valley, AZ | 1 | $2.8 million | 0 | $0 |
| Ocean State Research Institute, Inc. | Providence, RI | 3 | $2.8 million | 0 | $0 |
| University of Kansas Medical Center | Kansas City, KS | 1 | $2.8 million | 0 | $0 |
| National Jewish Health | Denver, CO | 2 | $2.7 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 2 | $2.7 million | 0 | $0 |
| Florida International University | Miami, FL | 2 | $2.7 million | 0 | $0 |
| Emory University | Atlanta, GA | 3 | $2.6 million | 0 | $0 |
| Ayuvis Research, Inc. | Fort Worth, TX | 2 | $2.6 million | 0 | $0 |
| Palo Alto Veterans Instit for Research | Palo Alto, CA | 1 | $2.5 million | 0 | $0 |
| Vasculonics, LLC | Indianapolis, IN | 1 | $2.4 million | 0 | $0 |
| Vascular Biosciences | San Diego, CA | 1 | $2.3 million | 0 | $0 |
| Eko Devices, Inc. | Oakland, CA | 1 | $2.3 million | 0 | $0 |
| Sensydia Corporation | Los Angeles, CA | 1 | $2.2 million | 0 | $0 |
| Shape Medical Systems, Inc. | Saint Paul, MN | 1 | $2.1 million | 0 | $0 |
| Virginia Polytechnic Institute and State University | Blacksburg, VA | 3 | $2 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 4 | $1.9 million | 0 | $0 |
| Bridgesource Medical Corporation | Austin, TX | 1 | $1.9 million | 0 | $0 |
| Aqualung Therapeutics Corp. | Juno Beach, FL | 1 | $1.9 million | 0 | $0 |
| Third Pole, Inc. | Waltham, MA | 1 | $1.8 million | 0 | $0 |
| Nota Laboratories, LLC | Ann Arbor, MI | 1 | $1.7 million | 0 | $0 |
| Rush University Medical Center | Chicago, IL | 1 | $1.6 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 1 | $1.5 million | 0 | $0 |
| Texas Tech University Health Scis Center | Lubbock, TX | 1 | $1.4 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 1 | $1.4 million | 0 | $0 |
| Research Inst Nationwide Children's Hosp | Columbus, OH | 1 | $1 million | 0 | $0 |
| Board of Regents, NSHE, obo University of Nevada, Reno | Reno, NV | 1 | $987,668 | 0 | $0 |
| University of South Florida | Tampa, FL | 2 | $940,763 | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 1 | $936,858 | 0 | $0 |
| University of Wyoming | Laramie, WY | 2 | $864,083 | 0 | $0 |
| Cedars-Sinai Medical Center | Los Angeles, CA | 2 | $811,351 | 0 | $0 |
| Methodist Hospital Research Institute | Houston, TX | 1 | $760,708 | 0 | $0 |
| California Northstate University | Elk Grove, CA | 1 | $727,284 | 0 | $0 |
| University of Missouri-Columbia | Columbia, MO | 1 | $658,885 | 0 | $0 |
| Brown University | Providence, RI | 1 | $657,427 | 0 | $0 |
| Texas A&M Engineering Experiment Station | College Station, TX | 1 | $642,045 | 0 | $0 |
| University of California-Berkeley | Berkeley, CA | 1 | $638,990 | 0 | $0 |
| University of Cincinnati | Cincinnati, OH | 1 | $618,300 | 0 | $0 |
| Michigan State University | East Lansing, MI | 1 | $610,107 | 0 | $0 |
| Medical College of Wisconsin | Milwaukee, WI | 1 | $608,252 | 0 | $0 |
| Beth Israel Deaconess Medical Center | Boston, MA | 1 | $573,856 | 0 | $0 |
| University of Iowa | Iowa City, IA | 1 | $550,567 | 0 | $0 |
| Sentara Health | Virginia Beach, VA | 1 | $543,703 | 0 | $0 |
| Lundquist Institute for Biomedical Innovation at Harbor-Ucla Medical Center | Torrance, CA | 1 | $507,399 | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 1 | $455,826 | 0 | $0 |
| Medluidics LLC | Elk Grove, CA | 1 | $426,671 | 0 | $0 |
| Cornell University | Ithaca, NY | 1 | $407,391 | 0 | $0 |
| New York Medical College | Valhalla, NY | 1 | $405,909 | 0 | $0 |
| Metfora LLC | Vail, AZ | 1 | $373,684 | 0 | $0 |
| Hunterian Medicine LLC | Cambridge, MA | 1 | $350,000 | 0 | $0 |
| Pennsylvania State Univ Hershey Med CTR | Hershey, PA | 1 | $347,238 | 0 | $0 |
| Glycoscientific, LLC | Athens, GA | 1 | $275,767 | 0 | $0 |
| Kaiser Foundation Research Institute | Oakland, CA | 1 | $248,979 | 0 | $0 |
| SUNY at Binghamton | Binghamton, NY | 1 | $244,589 | 0 | $0 |
| University of Delaware | Newark, DE | 1 | $224,886 | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 187 | $97,914,277 | 0 | $0 |
| 2024 | 204 | $108,514,316 | 0 | $0 |
| 2023 | 202 | $104,000,709 | 0 | $0 |
| 2022 | 183 | $93,051,462 | 0 | $0 |
| 2021 | 119 | $64,301,701 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.